Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Don M. Benson, Jr., MD PhD, Houston Holmes, MD, Parameswaran Hari, MBBS, MD, Jessica Sachs, MD, Ben Exter, Ann Ranger, PhD, Tooba Cheema, PhD, Iga Sienczylo, BS, Megan M. O'Meara, MD, Django Sussman, PhD, Luke P. Akard, MD

Blood (2018) 132 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2018-99-111729

Published: 2018

Journal Articles

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, Anjali S. Advani, Daniel J. DeAngelo, Tibor J. Kovacsovics, Anand Jillella, Dale Bixby, Moshe Y. Levy, Megan M. O’Meara, Phoenix A. Ho, Jenna Voellinger, Anthony S. Stein

Blood (2018) 132 (11): 1125–1133.

https://doi.org/10.1182/blood-2018-03-841171

Published: 2018

Journal Articles

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Eytan M. Stein, Roland B. Walter, Harry P. Erba, Amir T. Fathi, Anjali S. Advani, Jeffrey E. Lancet, Farhad Ravandi, Tibor Kovacsovics, Daniel J. DeAngelo, Dale Bixby, Stefan Faderl, Anand P. Jillella, Phoenix A. Ho, Megan M. O’Meara, Baiteng Zhao, Charles Biddle-Snead, Anthony S. Stein

Blood (2018) 131 (4): 387–396.

https://doi.org/10.1182/blood-2017-06-789800

Published: 2018

Includes: Supplemental data

Journal Articles

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Eytan M. Stein, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Roland B. Walter, MD PhD MS, Anjali Advani, MD, Daniel J. DeAngelo, MD PhD, Tibor J. Kovacsovics, MD, Anand P Jillella, MD, Dale L. Bixby, MD PhD, Moshe Y Levy, MD, Megan M. O'Meara, MD, Phoenix Ho, MD, Anthony S. Stein, MD

Blood (2016) 128 (22): 591.

https://doi.org/10.1182/blood.V128.22.591.591

Published: 2016

Journal Articles

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

Dale L. Bixby, MD PhD, Anthony S. Stein, MD, Amir T. Fathi, MD, Tibor J. Kovacsovics, MD, Moshe Y Levy, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Roland B. Walter, MD PhD MS, Eytan M. Stein, MD, Stefan Faderl, MD, Daniel J. DeAngelo, MD PhD, Phoenix Ho, MD, Megan M. O'Meara, MD, Jenna L Voellinger, PhD, Anjali Advani, MD

Blood (2016) 128 (22): 590.

https://doi.org/10.1182/blood.V128.22.590.590

Published: 2016

Journal Articles

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

Amir T. Fathi, MD, Harry P Erba, MD PhD, Jeffrey E Lancet, MD, Eytan M Stein, Roland B. Walter, MD PhD MS, Daniel J. DeAngelo, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Anjali S. Advani, MD, Dale Bixby, MD PhD, Tibor J. Kovacsovics, MD, Megan M. O'Meara, MD, Dana A. Kennedy, PharmD, Anthony S. Stein, MD

Blood (2015) 126 (23): 454.

https://doi.org/10.1182/blood.V126.23.454.454

Published: 2015

Journal Articles

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Christine O'Day, PhD, Steve Alley, PhD, Martha Anderson, Kim Emmerton, Weipeng Zeng, Megan M. O'Meara, MD, Eric J. Feldman, MD, Dana A. Kennedy, Maureen C. Ryan, PhD, Dennis Benjamin, PhD

Blood (2015) 126 (23): 3785.

https://doi.org/10.1182/blood.V126.23.3785.3785

Published: 2015

Journal Articles

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Anthony S. Stein, MD, Roland B. Walter, MD PhD MS, Harry P Erba, MD PhD, Amir T. Fathi, MD, Anjali S. Advani, MD, Jeffrey E Lancet, MD, Farhad Ravandi, MD, Tibor J. Kovacsovics, MD, Daniel J. DeAngelo, MD PhD, Dale Bixby, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Megan M. O'Meara, MD, Baiteng Zhao, PhD, Eytan M Stein

Blood (2015) 126 (23): 324.

https://doi.org/10.1182/blood.V126.23.324.324

Published: 2015

Journal Articles

Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Eytan M. Stein, Anthony Stein, Roland B. Walter, MD PhD MS, Amir T. Fathi, MD, Jeffrey E. Lancet, MD, Tibor J. Kovacsovics, MD, Anjali S. Advani, MD, Daniel J DeAngelo, Megan M. O'Meara, MD, Baiteng Zhao, PhD, Dana A. Kennedy, PharmD, BCOP, Harry P. Erba, MD PhD

Blood (2014) 124 (21): 623.

https://doi.org/10.1182/blood.V124.21.623.623

Published: 2014

Journal Articles

SGN-CD33A in Combination with Cytarabine or Hypomethylating Agents Demonstrates Enhanced Anti-Leukemic Activity in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, MD, Martha Anderson, Kim Emmerton, Weiping Zeng, MD, Megan M. O'Meara, MD, Dana A. Kennedy, PharmD, BCOP, Maureen C. Ryan, PhD, Dennis R. Benjamin, PhD

Blood (2014) 124 (21): 3739.

https://doi.org/10.1182/blood.V124.21.3739.3739

Published: 2014

Journal Articles

A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

Uma Borate, MD, Amir T. Fathi, MD, Bijal D. Shah, MD, Daniel J. DeAngelo, MD, Ph.D, Lewis B. Silverman, MD, Todd Michael Cooper, Tina M. Albertson, MD, PhD, Megan M. O'Meara, MD, Larissa Sandalic, MS, Faith Stevison, MS, Robert Chen, MD

Blood (2013) 122 (21): 1437.

https://doi.org/10.1182/blood.V122.21.1437.1437

Published: 2013

Journal Articles

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Christopher A. Yasenchak, MD, Robert Chen, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Beata Holkova, MD, Peter J. Rosen, MD, Jonathan W. Friedberg, MD, Megan M. O'Meara, MD, Andres Forero-Torres, MD

Blood (2013) 122 (21): 4389.

https://doi.org/10.1182/blood.V122.21.4389.4389

Published: 2013

Journal Articles

Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies

Michelle A. Fanale, MD, Nancy L. Bartlett, MD, Andres Forero-Torres, MD, Anas Younes, MD, Robert W. Chen, MD, Jonathan W. Friedberg, MD, Jeffrey V. Matous, MD, Andrei R. Shustov, MD, Scott E. Smith, MD, PhD, Jasmine Zain, MD, Megan M. O'Meara, MD, Ajay K. Gopal, MD

Blood (2012) 120 (21): 3687.

https://doi.org/10.1182/blood.V120.21.3687.3687

Published: 2012

Journal Articles

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma

Stephen M. Ansell, M.D., Ph.D., Joseph M. Connors, MD, Steven I. Park, MD, Megan M. O'Meara, MD, Anas Younes, MD

Blood (2012) 120 (21): 798.

https://doi.org/10.1182/blood.V120.21.798.798

Published: 2012

NARROW

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

SGN-CD33A in Combination with Cytarabine or Hypomethylating Agents Demonstrates Enhanced Anti-Leukemic Activity in Preclinical Models of AML

A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only